Normal endocervical epithelium usually expressed cyclin D1, although staining was typically focal, and there was increased immunoreactivity in reactive and metaplastic glandular cells including tubo-endometrioid metaplasia. ❋ Leonie Little (2010)
Previous studies have correlated their overexpression with poor prognosis and decreased tumor-infiltrating lymphocytes in various carcinomas including uterine endometrioid carcinomas, and mounting evidence supports an immuno-inhibitory role in ovarian cancer prognosis. ❋ Xingxing Zang (2010)
"Overall, 46 percent of patients with ovarian clear-cell carcinoma and 30 percent of those with endometrioid carcinoma had ... mutations in ARID1A," they wrote. ❋ Unknown (2010)
Pathological analyses showed the predominance of endometrioid type (24. 4%) and clear-cell type (21. 9%) types in EAOC compared to OC, P = 0.0070 and 0.0029, respectively. ❋ Aziz Aris (2010)
Inclusion criteria: Patients with a clinical stage I endometrioid adenocarcinoma or complex atypical hyperplasia are randomized in a 2: 1 allocation to receive TLH or TAH. ❋ Unknown (2009)
Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, et al. (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt / beta-catenin and PI3K / Pten signaling pathways. ❋ Unknown (2009)
Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, et al. (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. ❋ Unknown (2009)
An endometrioma, endometrioid cyst, endometrial cyst, or chocolate cyst is caused by endometriosis, and formed when a tiny patch of endometrial tissue (the mucous membrane that makes up the inner layer of the uterine wall) bleeds, sloughs off, becomes transplanted, and grows and enlarges inside the ovaries. ❋ Unknown (2008)
"This targeted approach holds great promise for patients with uterine cancer (endometrioid endometrial) tumors that contain the FGFR2 mutation" said TGen physician-in-chief, Dr. Daniel Von Hoff, "and offers yet another powerful example of how genomic medicine is changing the way we look at and treat cancer" ❋ Unknown (2008)
The altered FGFR2 is present in the cancer cells of nearly 15 percent of women with endometrioid endometrial tumors. ❋ Unknown (2008)
While many women are successfully treated with these approaches, about 15 percent of those with endometrioid endometrial cancer have persistent or recurring tumors that are resistant to current drug therapies. ❋ Unknown (2008)
Dr. Pamela Pollock, an associate investigator in TGen's Cancer and Cell Biology Division and the paper's senior author, led a team that used the latest genome-scanning technology to sequence 116 endometrioid endometrial tumor samples. ❋ Unknown (2008)
(high-grade serous, clear cell, endometrioid, mucinous, and low-grade serous) are distinct diseases that can be reproducibly diagnosed2 and that vary with respect to characteristics of the precursor lesions, the genetic events during oncogenesis, and response to chemotherapy. 4 These subtypes have distinct biomarker-expression profiles. 5 In cohorts of patients with ovarian carcinoma consisting of a mixture of subtypes, ❋ Unknown (2009)
[9] is able to induce endometrioid ovarian tumors in mice in vivo. ❋ Unknown (2009)
